Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY12 | Q9H244 | 16/20 | 0.79 |
| ▸ | PGR | P06401 | 1/20 | 0.79 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.79 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.79 |
| ▸ | DRD1 | P21728 | 1/20 | 0.79 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.79 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.79 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.79 |
| ▸ | FPR3 | P25089 | 1/20 | 0.79 |
| ▸ | PDE4A | P27815 | 1/20 | 0.79 |
| ▸ | GPR183 | P32249 | 1/20 | 0.79 |
| ▸ | DRD3 | P35462 | 1/20 | 0.79 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.79 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.79 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.79 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.79 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.79 |
| ▸ | P2RY13 | Q9BPV8 | 1/20 | 0.79 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2612407 | 1.00 | P2RY12 (0.79) | P2RY12PGRADORA3CHRM1DRD1 | |
| SCHEMBL13192071 | 1.00 | P2RY12 (0.79) | P2RY12PGRADORA3CHRM1DRD1 | |
| SCHEMBL16142521 | 1.00 | P2RY12 (0.79) | P2RY12PGRADORA3CHRM1DRD1 | |
| SCHEMBL17551052 | 1.00 | P2RY12 (0.79) | P2RY12PGRADORA3CHRM1DRD1 | |
| SCHEMBL18673991 | 1.00 | P2RY12 (0.79) | P2RY12PGRADORA3CHRM1DRD1 | |
| SCHEMBL18019292 | 1.00 | P2RY12 (0.79) | P2RY12PGRADORA3CHRM1DRD1 | |
| SCHEMBL5962540 | 1.00 | P2RY12 (0.79) | P2RY12PGRADORA3CHRM1DRD1 | |
| SCHEMBL18673846 | 1.00 | P2RY12 (0.79) | P2RY12PGRADORA3CHRM1DRD1 | |
| SCHEMBL12280745 | 1.00 | P2RY12 (0.79) | P2RY12PGRADORA3CHRM1DRD1 | |
| SCHEMBL17244414 | 1.00 | P2RY12 (0.79) | P2RY12PGRADORA3CHRM1DRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 92 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2016030704-A1 | SOLID FORM OF INTERMEDIATE OF TICAGRELOR | CIPLA LIMITED (IN) | 2016-03-03 | — | — | WO | claimed |
| US-12391768-B2 | Antibodies to ticagrelor and methods of use | MEDIMMUNE LIMITED (GB) | 2025-08-19 | — | — | US | disclosed |
| US-20240101712-A1 | ANTIBODIES TO TICAGRELOR AND METHODS OF USE | MEDIMMUNE LTD (GB) | 2024-03-28 | — | — | US | disclosed |
| US-20230322784-A1 | Process for the Preparation of Ticagrelor | ZAKLADY FARMACEUTYCZNE POLPHARMA S.A. (PL) | 2023-10-12 | — | — | US | disclosed |
| US-11773186-B2 | Antibodies to ticagrelor and methods of use | MEDIMMUNE LIMITED (GB) | 2023-10-03 | — | — | US | disclosed |
| US-20210371546-A1 | ANTIBODIES TO TICAGRELOR AND METHODS OF USE | MEDIMMUNE LTD (GB) | 2021-12-02 | — | — | US | disclosed |
| US-10954308-B2 | Antibodies to ticagrelor and methods of use | MEDIMMUNE LIMITED (GB) | 2021-03-23 | — | — | US | disclosed |
| US-10487154-B2 | Antibodies to ticagrelor and methods of use | MEDIMMUNE LIMITED (GB) | 2019-11-26 | — | — | US | disclosed |
| EP-2755957-B2 | SYNTHESIS OF TRIAZOLOPYRIMIDINE COMPOUNDS | LEK PHARMACEUTICALS (SI) | 2019-05-15 | — | — | EP | disclosed |
| EP-2755957-B2 | SYNTHESIS OF TRIAZOLOPYRIMIDINE COMPOUNDS | LEK PHARMACEUTICALS (SI) | 2019-05-15 | — | — | EP | disclosed |
| US-20110218330-A1 | Novel triazolo pyrimidine compounds | ASTRAZENECA AB (SE) | 2011-09-08 | — | — | US | disclosed |
| WO-2011017108-A2 | CYCLOPROPYL MODULATORS OF P2Y12 RECEPTOR | AUSPEX PHARMACEUTICALS, INC. (US) | 2011-02-10 | — | — | WO | disclosed |
| US-20100004444-A1 | Novel Triazolo pyrimidine compounds | ASTRAZENECA AB (SE) | 2010-01-07 | — | — | US | disclosed |
| US-20080234481-A1 | Novel triazolo pyrimidine compounds | ASTRAZENECA AB (SE) | 2008-09-25 | — | — | US | disclosed |
| US-7381828-B2 | Triazolo pyrimidine compounds | AstraZēneca AB (SE) | 2008-06-03 | — | — | US | disclosed |
| EP-1299390-B1 | PYRIMIDINE COMPOUNDS AND THEIR USE IN THE PREPARATION OF A TRIAZOLO -PYRIMIDINE CARBA NUCLEOSIDE | ASTRAZENECA AB (SE) | 2008-02-13 | — | — | EP | disclosed |
| US-20070049755-A1 | Novel triazolo pyrimidine compounds | ASTRAZENECA AB (SE) | 2007-03-01 | — | — | US | disclosed |
| US-7067663-B2 | Triazolo pyrimidine compounds | ASTRAZENECA AB (SE) | 2006-06-27 | — | — | US | disclosed |
| US-20060041132-A1 | Novel triazolo pyrimidine compounds | ASTRAZENECA AB (SE) | 2006-02-23 | — | — | US | disclosed |
| US-20030148888-A1 | Novel triazolo pyrimidine compounds | ASTRAZENECA AB (SE) | 2003-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030148888-A1 | Novel triazolo pyrimidine compounds | TYMS, TYMP, DPYD | P2RY12 191/4885PGR 2439/4885ADORA3 320/4885 |
| US-20070049755-A1 | Novel triazolo pyrimidine compounds | TYMS, TYMP, DPYD | P2RY12 191/4885PGR 2439/4885ADORA3 320/4885 |
| US-20080234481-A1 | Novel triazolo pyrimidine compounds | TYMS, TYMP, DPYD | P2RY12 191/4885PGR 2439/4885ADORA3 320/4885 |
| US-20060041132-A1 | Novel triazolo pyrimidine compounds | TYMS, TYMP, DPYD | P2RY12 191/4885PGR 2439/4885ADORA3 320/4885 |
| US-20240101712-A1 | ANTIBODIES TO TICAGRELOR AND METHODS OF USE | NT5C2, GP6, P2RY6 | P2RY12 9/4885PGR 500/4885ADORA3 17/4885 |
| US-10954308-B2 | Antibodies to ticagrelor and methods of use | NT5C2, GP6, P2RY6 | P2RY12 9/4885PGR 500/4885ADORA3 17/4885 |
| US-12391768-B2 | Antibodies to ticagrelor and methods of use | NT5C2, GP6, P2RY6 | P2RY12 9/4885PGR 500/4885ADORA3 17/4885 |
| US-20230322784-A1 | Process for the Preparation of Ticagrelor | TH, NT5C, P2RY6 | P2RY12 27/4885PGR 3019/4885ADORA3 95/4885 |
| US-11773186-B2 | Antibodies to ticagrelor and methods of use | NT5C2, GP6, P2RY6 | P2RY12 9/4885PGR 500/4885ADORA3 17/4885 |
| US-20210371546-A1 | ANTIBODIES TO TICAGRELOR AND METHODS OF USE | NT5C2, GP6, P2RY6 | P2RY12 9/4885PGR 500/4885ADORA3 17/4885 |
| US-20100004444-A1 | Novel Triazolo pyrimidine compounds | TYMS, TYMP, DPYD | P2RY12 191/4885PGR 2439/4885ADORA3 320/4885 |
| US-20110218330-A1 | Novel triazolo pyrimidine compounds | TYMS, TYMP, DPYD | P2RY12 191/4885PGR 2439/4885ADORA3 320/4885 |
| US-10487154-B2 | Antibodies to ticagrelor and methods of use | NT5C2, GP6, P2RY6 | P2RY12 9/4885PGR 500/4885ADORA3 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.